Law360, San Diego (July 07, 2011, 7:05 PM ET) -- The Federal Circuit on Thursday affirmed that Watson Laboratories Inc.’s generic version of congestion reliever Mucinex did not infringe a Reckitt Benckiser Inc. patent.
The appeals court found that the district court correctly construed the claims of U.S. Patent Number 6,372,252, and determined that because Watson’s generic version had a different formulation than the branded drug, it did not violate the patent.
Reckitt sued Watson in the Southern District of Florida in April 2009, claiming the defendant's abbreviated new drug application to market guaifenesin tablet formulations...
Watson Didn’t Infringe Mucinex Patent: Fed. Circ.
To view the full article, take a free trial now.
